Physician profile
Jerome D Cohen
NPI 1922036474
$23,656.57
in general payments reported to CMS, 2019-2025
43 companies · $1,847 in 2025
The $1,847 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,315 · 2020: $6,868 · 2021: $1,235 · 2022: $1,240 · 2023: $1,444 · 2024: $1,708 · 2025: $1,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,825 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,824.63 |
| Education | $174.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,632.71 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Gilead Sciences, INC. | $2,566.49 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $2,000.00 | 2020 | |
| Janssen Biotech, INC. | $1,331.81 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $717.03 | 2019-2024 | Xifaxan |
| Celgene Corporation | $521.84 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $508.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $455.03 | 2019-2025 | Linzess |
| Boston Scientific Corporation | $392.63 | 2019-2022 | |
| Ardelyx, INC. | $340.89 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $265.67 | 2019-2025 | Gattex, Entyvio, Eohilia |
| Pfizer INC. | $250.42 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $198.88 | 2019-2021 | |
| Organon LLC | $134.68 | 2021-2024 | Hadlima, Renflexis |
| Ipsen Biopharmaceuticals, INC | $114.80 | 2024-2025 | Iqirvo, Bylvay |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $112.82 | 2019-2023 | Ocaliva |
| Aimmune Therapeutics, INC. | $107.04 | 2023-2025 | Vowst |
| Olympus America INC. | $100.00 | 2025 | Endoclot Phs, Olympus, Visiglide |
| Genzyme Corporation | $81.51 | 2023-2025 | |
| Redhill Biopharma INC. | $78.90 | 2020-2024 | Talicia |
| Nestle Healthcare Nutrition INC. | $74.65 | 2021-2022 | |
| Lilly USA, LLC | $73.93 | 2024-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $73.47 | 2024 | Stelara |
| Celltrion USA INC. | $72.68 | 2023-2025 | Yuflyma, Vegzelma |
| 3-D Matrix, INC. | $47.12 | 2024 | |
| Amgen INC. | $42.63 | 2021 | |
| Alfasigma USA, INC. | $41.46 | 2020-2021 | |
| Csl Behring | $39.67 | 2019-2020 | |
| Romark Laboratories, Lc | $36.36 | 2019 | |
| Phathom Pharmaceuticals, INC. | $31.45 | 2024 | Voquezna |
| Ucb, INC. | $26.87 | 2019 | |
| Allergan, INC. | $23.12 | 2019-2020 | |
| Novo Nordisk INC | $21.84 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $21.08 | 2024 | Dupixent |
| Tetraphase Pharmaceuticals, INC. | $18.27 | 2019 | |
| Intra-Sana Laboratories | $16.21 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Alnylam Pharmaceuticals INC. | $15.90 | 2022 | |
| Exact Sciences Corporation | $15.04 | 2024 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $14.44 | 2023 | Rebyota |
| Shionogi INC | $14.37 | 2019 | |
| W. L. Gore & Associates, INC. | $12.78 | 2020 | |
| Endo Pharmaceuticals INC. | $11.95 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$60,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.